Stability of unused reconstituted bortezomib in original manufacturer vials

Journal of Oncology Pharmacy Practice

Volumn 17, Issue 4, 2011, Pages 400-402

  Vanderloo, Joshua P ^a   Pomplun, Marcia L ^b   Vermeulen, Lee C ^a,c   Kolesar, Jill M ^a,b  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c University of Wisconsin Health   (United States)

Author keywords

Bortezomib; mantle cell carcinoma; multiple myeloma; renal transplantation; stability

Indexed keywords

BORTEZOMIB;

ARTICLE; COST CONTROL; DRUG INDICATION; DRUG MANUFACTURE; DRUG STABILITY; DRUG STORAGE; KIDNEY GRAFT REJECTION; LIQUID CHROMATOGRAPHY; MANTLE CELL LYMPHOMA; MASS SPECTROMETRY; MULTIPLE MYELOMA; PRIORITY JOURNAL;

BORONIC ACIDS; CHROMATOGRAPHY, LIQUID; DRUG PACKAGING; DRUG STABILITY; DRUG STORAGE; MASS SPECTROMETRY; PYRAZINES; TANDEM MASS SPECTROMETRY; TIME FACTORS;

EID: 82555171613     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155210386268     Document Type: Article

References (6)

1. Velcade (bortezomib) package insert. Cambridge, MA: Millennium Pharmaceuticals, 2009.
2. Everly M, Everly J, Susskind B, et al. Bortezomib provides effective therapy for antibody and cell-mediated acute rejection. Transplantation. 2008 ; 86: 1754-1761
3. Trivedi H, Terasaki P, Feroz A, et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation. 2009 ; 87: 1555-1561
4. André P, Cisternino S, Chiadmi F, et al. Stability of bortezomib 1-mg/mL solution in plastic syringe and glass vial. Ann Pharmacother. 2005 ; 39: 1462-1466 (Pubitemid 41197127)
5. Nichols C, Welsh OJ. AJHP policy on manuscripts dealing with drug stability. Am J Hosp Pharm. 1988 ; 45: 1571-1572
6. Trissel L, Flora K. Stability studies: five years later. Am J Hosp Pharm. 1988 ; 45: 1569-1571